Clinical Trial Update: A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing. [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating the effects of SB756050 after six days of dosing in subjects with Type 2 diabetes mellitus. The study status is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SB756050

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED